Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Cannabidiol (CBD) in Persons With Multiple Sclerosis (MS)
NCT05269628Phase 2Recruiting
- Start
- Mar 2022
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol and dronabinol in multiple sclerosis (MS) (4 arms). Primary endpoints: Mean change in sleep bout length at 12 weeks, Change in Walsh Spectral Entropy at 12 weeks and 5 more. Started Mar 2022; status: recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05269628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269628.